MindMaze Therapeutics Holding SA / Key word(s): MiscellaneousMindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing10-Aug-2026 / 07:00 CET/CESTRelease of an ad hoc announcement pursuant to Art. Update on Neuro.io Equity FinancingSeparately, the Company provided an update on its CHF 8.0 million strategic equity financing with Neuro.io. Alongside the Neuro.io financing, the Company is actively pursuing additional financing to support its liquidity and will provide further updates as material developments occur. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. With an extensive library of rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.